July 2011
Contract Pharma;Jul/Aug2011, Vol. 13 Issue 6, p94
Trade Publication
The article reports on the performance of Leverkusen, Germany-based Bayer Healthcare AG in 2010 and its prospects for growth in 2011.


Related Articles

  • Company Showcase.  // Contract Pharma;Oct2010, Vol. 12 Issue 8, p114 

    The article offers information on several pharmaceutical companies in the U.S. It notes that Advantar Laboratories Inc. located in San Diego California has tools to accelerate product development. It mentions that Avema Pharma Solutions located in Miami Florida offers services related the...

  • CLINIC ROUNDUP.  // BioWorld Today;5/20/2008, Vol. 19 Issue 98, p4 

    This section offers news briefs on the pharmaceutical industry in 2008. Bayer HealthCare AG and Nektar Therapeutics Inc of San Carlos, California have developed a drug-device combination called Amikacin Inhale which can treat pneumonia. Epeius Biotechnologies Corp. reported positive study...

  • PHARMA: OTHER NEWS TO NOTE.  // BioWorld Today;12/6/2013, Vol. 24 Issue 234, p8 

    This section offers news briefs on the pharmaceutical industry. An investment of 250 million dollars is planned by Alvotech to develop and manufacture biosimilar monoclonal antibodies. Johnson & Johnson unit Janssen has partnered with CSL Ltd to develop and globally commercialize CSL362...

  • Halving Treatment Time. Breitstein, Jonna; N. T. M. // Pharmaceutical Executive;Nov2005, Vol. 25 Issue 11, p24 

    Reports on the collaboration between Bayer HealthCare AG and the Global Alliance for TB Drug Development. Significance of the collaboration for the improvement in the treatment of tuberculosis; Terms under the deal; Importance of the partnership to the pharmaceutical industry.

  • COMPANY SPOTLIGHT -- Bayer AG.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p19 

    The article presents a corporate profile for pharmaceutical company Bayer Healthcare AG in the U.S. Bayer is the holding company of the Bayer Group with approximately 320 consolidated companies worldwide and offers a range of products including ethical pharmaceuticals, agricultural products and...

  • Bayer Spin-Off AiCuris Licenses Phase III-Ready Antiviral to Merck & Co. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 11, p140 

    Merck & Co. has licensed global rights to Bayer HealthCare spin-off AiCuris' portfolio of human cytomegalovirus (HCMV)-targeting drug candidates in a deal worth up to €442.5 M (US$573 M). The HCMV portfolio includes AiCuris' lead product letermovir (AIC246), which met its primary efficacy...

  • Bayer Divests Stake in Millennium Pharma.  // Chemical Market Reporter;11/3/2003, Vol. 264 Issue 15, p2 

    Reports on the end in the research collaboration between Bayer Healthcare AG and Millennium Pharmaceuticals Inc. Sale of the shares of Bayer in the biopharmaceutical firm; Aim of Bayer to reduce its net debt; Benefits of the sale for the company.

  • The Industry.  // Pharmaceutical Representative;Dec2008, Vol. 38 Issue 12, p10 

    The article offers pharmaceutical business related news briefs worldwide. The company Norvatis announces its new regional business model in the U.S. The European Union and Canada have approved the Bayer Healthcare's once-daily anticoagulant drug Xarelto. The pharmaceutical company Biovitrum AB...

  • Bayer Prods Consumers to Take Another Look at Aspirin.  // Chain Drug Review;5/21/2012, Vol. 34 Issue 9, p64 

    The article offers news briefs related to the U.S. pharmaceutical industry on topics including a new consumer campaign launched by Bayer Healthcare AG, construction delay in Johnson & Johnson Services Inc.'s factory in Pennsylvania, and shipping of guaifenesin extended-release tablets by Perrigo Co.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics